- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02510040
A Prospective Observational Study of Adult Strabismus (SAS1)
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Virginia
-
Norfolk, Virginia, United States, 23502-3942
- Earl R. Crouch, III
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Eligibility Criteria for Convergence Insufficiency (CI) Group:
The following inclusion criteria must be met for the subject to be enrolled into the study:
- Adults ≥18 years of age (adult onset of CI not required)
- No strabismus surgery within the past 10 years
- CI Symptom Survey score ≥21 points
- Near exodeviation of ≥4∆ and at least 4∆ larger than at distance by PACT
- Distance exodeviation ≤15∆ by PACT
- Vertical deviation ≤2∆ at distance and near by PACT
- No constant exotropia at distance or near
- Reduced positive fusional vergence (PFV) at near (<20∆ or fails Sheard's criterion that the PFV measures less than twice the magnitude of the near phoria)
- Near point of convergence (NPC) of ≥6 cm break
- Visual acuity 20/50 or better in both eyes by ETDRS or Snellen
- No paralytic strabismus (e.g., 3rd, 4th, or 6th cranial nerve palsies, skew deviation, Duane syndrome)
- No restrictive strabismus (e.g., blowout fracture, thyroid eye disease, post scleral buckle, Brown syndrome)
- No monocular diplopia
- No paretic strabismus, thyroid eye disease, myasthenia gravis, chronic progressive external ophthalmoplegia, or eye movement abnormalities associated with known neurological disease. Patients with Parkinson's disease can be enrolled if non-paretic deviation.
- No inferior or superior oblique overaction defined as 2+ or greater
- Ability to fuse with prism in space (see section 2.4.1)
- Ability to understand and complete a survey
- Investigator is initiating treatment with prism, orthoptic exercises, botulinum toxin injection or surgery
- If initiating treatment with botulinum toxin or surgery, planned injection or surgery to be within 60 days of enrollment
- Single treatment modality is planned (e.g., no combined prism and orthoptic exercises)
- Treatment to be initiated has not been used within the past one year
Eligibility Criteria for Divergence Insufficiency (DI) Group:
The following inclusion criteria must be met for the subject to be enrolled into the study:
- Adults ≥18 years of age
- Adult-onset DI (at ≥18 years of age)
- No prior strabismus surgery
- Symptoms of diplopia at distance with a frequency of sometimes or worse in primary position (in current glasses if wearing glasses)
- Distance esodeviation of 2∆ to 30∆ and at least 50% larger than at near by PACT
- No more than 5∆ difference between right and left gaze by PACT
- No more than 10∆ difference between the primary position at distance and either upgaze or downgaze ≤10∆ by PACT
- Any coexisting vertical deviation must be less than distance esodeviation and ≤10∆ by PACT
- Visual acuity 20/50 or better in both eyes by ETDRS or Snellen
- No paralytic strabismus (e.g., 3rd, 4th, or 6th cranial nerve palsies, skew deviation, Duane syndrome)
- No restrictive strabismus (e.g., blowout fracture, thyroid eye disease, post scleral buckle, Brown syndrome)
- No monocular diplopia
- No paretic strabismus, thyroid eye disease, myasthenia gravis, chronic progressive external ophthalmoplegia, or eye movement abnormalities associated with known neurological disease. Patients with Parkinson's disease can be enrolled if non-paretic deviation
- No inferior or superior oblique overaction defined as 2+ or greater
- Ability to fuse with prism in space (see section 2.4.2)
- Ability to understand and complete a survey
- Investigator is initiating treatment with prism, orthoptic exercises, botulinum toxin injection or surgery
- If initiating treatment with botulinum toxin or surgery, planned injection or surgery to be within 60 days of enrollment
- Single treatment modality planned (e.g., no combined prism and orthoptic exercises)
- Treatment to be initiated has not been used within the past one year
Eligibility Criteria for Small-angle Hypertropia (HT) Group:
The following inclusion criteria must be met for the subject to be enrolled into the study:
- Adults ≥18 years of age
- Adult-onset HT (at ≥18 years of age)
- No prior strabismus surgery
- Symptoms of diplopia at distance or near with a frequency of sometimes or worse in primary or reading position (in current glasses if wearing glasses)
- Vertical deviation ≥1∆ to ≤10∆ at distance and near by PACT
- No more than 4∆ difference from the primary in any gaze position by PACT
- Any coexisting esodeviation must be less than the vertical deviation
- Any coexisting exodeviation ≤10∆ by PACT
- No convergence insufficiency as defined in section 2.2.1
- Visual acuity 20/50 or better in both eyes by ETDRS or Snellen
- No paralytic strabismus (e.g., 3rd, 4th, or 6th cranial nerve palsies, skew deviation, Duane syndrome)
- No restrictive strabismus (e.g., blowout fracture, thyroid eye disease, post scleral buckle, Brown syndrome)
- No monocular diplopia
- No paretic strabismus, thyroid eye disease, myasthenia gravis, chronic progressive external ophthalmoplegia, or eye movement abnormalities associated with known neurological disease. Patients with Parkinson's disease can be enrolled if non-paretic deviation.
- No inferior or superior oblique overaction defined as 2+ or greater
- Ability to fuse with prism in space (see section 2.4.3)
- Ability to understand and complete a survey
- Investigator is initiating treatment with prism, orthoptic exercises, botulinum toxin injection or surgery
- If initiating treatment with botulinum toxin or surgery, planned injection or surgery to be within 60 days of enrollment
- Single treatment modality planned (e.g., no combined prism and orthoptic exercises)
- Treatment to be initiated has not been used within the past one year
Exclusion Criteria for Convergence Insufficiency (CI) Group:
The following criteria exclude a subject from enrollment into the study:
- Strabismus surgery within the past 10 years
- CI Symptom Survey score ≥21 points
- Near exodeviation of ≤4∆ and at least 4∆ larger than at distance by PACT
- Distance exodeviation ≥15∆ by PACT
- Vertical deviation ≥2∆ at distance and near by PACT
- Constant exotropia at distance or near
- Near point of convergence (NPC) of ≤6 cm break
- Visual acuity worse than 20/50 either eye by ETDRS or Snellen
- Paralytic strabismus (e.g., 3rd, 4th, or 6th cranial nerve palsies, skew deviation, Duane syndrome)
- Restrictive strabismus (e.g., blowout fracture, thyroid eye disease, post scleral buckle, Brown syndrome)
- Monocular diplopia
- Paretic strabismus, thyroid eye disease, myasthenia gravis, chronic progressive external ophthalmoplegia, or eye movement abnormalities associated with known neurological disease. Patients with Parkinson's disease can be enrolled if non-paretic deviation.
- Inferior or superior oblique overaction defined as 2+ or greater
- Inability to fuse with prism in space (see section 2.4.1)
- Inability to understand and complete a survey
- Treatment to be initiated has already been used within the past one year
Exclusion Criteria for Divergence Insufficiency (DI) Group:
The following criteria exclude a subject from enrollment into the study:
- No adult-onset DI (at ≥18 years of age)
- Prior strabismus surgery
- Distance esodeviation outside the range of 2∆ to 30∆ and less than 50% larger than at near by PACT
- More than 5∆ difference between right and left gaze by PACT
- More than 10∆ difference between the primary position at distance
- Any coexisting vertical deviation more than distance esodeviation and ≥10∆ by PACT
- Visual acuity worse than 20/50 in either eye by ETDRS or Snellen
- Paralytic strabismus (e.g., 3rd, 4th, or 6th cranial nerve palsies, skew deviation, Duane syndrome)
- Restrictive strabismus (e.g., blowout fracture, thyroid eye disease, post scleral buckle, Brown syndrome)
- Monocular diplopia
- Paretic strabismus, thyroid eye disease, myasthenia gravis, chronic progressive external ophthalmoplegia, or eye movement abnormalities associated with known neurological disease.
- Inferior or superior oblique overaction defined as 2+ or greater
- Inability to fuse with prism in space (see section 2.4.2)
- Inability to understand and complete a survey
- Treatment to be initiated has already been used within the past one year
Exclusion Criteria for Small-angle Hypertropia (HT) Group:
The following criteria exclude a subject from enrollment into the study:
- No adult-onset HT (at ≥18 years of age)
- Prior strabismus surgery
- Vertical deviation ≤1∆ or ≥10∆ at distance and near by PACT
- More than 4∆ difference from the primary in any gaze position by PACT
- Coexisting esodeviation must not be less than the vertical deviation
- Coexisting exodeviation ≥10∆ by PACT
- Convergence insufficiency as defined in section 2.2.1
- Visual acuity worse than 20/50 in either eye by ETDRS or Snellen
- Paralytic strabismus (e.g., 3rd, 4th, or 6th cranial nerve palsies, skew deviation, Duane syndrome)
- Restrictive strabismus (e.g., blowout fracture, thyroid eye disease, post scleral buckle, Brown syndrome)
- Monocular diplopia
- Paretic strabismus, thyroid eye disease, myasthenia gravis, chronic progressive external ophthalmoplegia, or eye movement abnormalities associated with known neurological disease.
- Inferior or superior oblique overaction defined as 2+ or greater
- Inability to fuse with prism in space (see section 2.4.3)
- Inability to understand and complete a survey
- Treatment to be initiated has already been used within the past one year
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Convergence insufficiency
Eligible adults with convergence insufficiency can be treated with prism, orthoptic exercises, eye muscle surgery, or botox injection, per the investigator's usual clinical practice.
|
Ground-in or Fresnel prism
Orthoptic exercises- fusion, convergence, divergence, and others, including computer-based therapy
Botulinum toxin injection
Other Names:
|
Divergence insufficiency
Eligible adults with divergence insufficiency can be treated with prism, orthoptic exercises, eye muscle surgery, or botox injection, per the investigator's usual clinical practice.
|
Ground-in or Fresnel prism
Orthoptic exercises- fusion, convergence, divergence, and others, including computer-based therapy
Botulinum toxin injection
Other Names:
|
Small-angle hypertropia
Eligible adults with small-angle hypertropia can be treated with prism, orthoptic exercises, eye muscle surgery, or botox injection, per the investigator's usual clinical practice.
|
Ground-in or Fresnel prism
Orthoptic exercises- fusion, convergence, divergence, and others, including computer-based therapy
Botulinum toxin injection
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Symptom Success at 10 Weeks
Time Frame: 10 weeks after enrollment
|
In the convergence insufficiency group, the primary outcome will be symptom success at the 10-week and 12-month visit, defined as improvement of CI Symptom Survey (CISS) score of at least 9 points and an outcome score of <21 points.
In the divergence insufficiency group, the primary outcome will be symptom success at the 10-week and 12-month visit, defined as diplopia "rarely" or "never" in primary position at distance on the diplopia questionnaire.
In the small-angle hypertropia group, the primary outcome will be symptom success at the 10-week and 12-month visit, defined as diplopia "rarely" or "never" both in primary position at distance and in reading position on the diplopia questionnaire.
|
10 weeks after enrollment
|
Number of Participants With Symptom Success at 12 Months
Time Frame: 12 months after enrollment
|
In the convergence insufficiency group, the primary outcome will be symptom success at the 10-week and 12-month visit, defined as improvement of CI Symptom Survey (CISS) score of at least 9 points and an outcome score of <21 points.
In the divergence insufficiency group, the primary outcome will be symptom success at the 10-week and 12-month visit, defined as diplopia "rarely" or "never" in primary position at distance on the diplopia questionnaire.
In the small-angle hypertropia group, the primary outcome will be symptom success at the 10-week and 12-month visit, defined as diplopia "rarely" or "never" both in primary position at distance and in reading position on the diplopia questionnaire.
|
12 months after enrollment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean of Near Point of Convergence in Convergence Insufficiency Group
Time Frame: 12 months after enrollment
|
Near point of convergence (convergence insufficiency group only).
|
12 months after enrollment
|
Mean Positive Fusional Vergence in Convergence Insufficiency Group
Time Frame: 12 months after enrollment
|
Positive fusional vergence (convergence insufficiency group only).
|
12 months after enrollment
|
Adult Strabismus 20 Questionnaire Score (DI)
Time Frame: 12 months after enrollment
|
Adult Strabismus Quality of Life Questionnaire (AS-20) For AS-20, scores are reported for the following subscales. A total score will not be reported.
|
12 months after enrollment
|
Mean Convergence Insufficiency Symptom Survey Score
Time Frame: 12 months after enrollment
|
Mean Convergence Insufficiency Symptom Survey Score (convergence insufficiency group only) For CISS, the range is from 0 (having no symptoms of CI) to 60 (always showing all symptoms of CI).
|
12 months after enrollment
|
Adult Strabismus 20 Questionnaire Score (CI)
Time Frame: 12 months after enrollment
|
Adult Strabismus Quality of Life Questionnaire (AS-20) For AS-20, scores are reported for the following subscales. A total score will not be reported. Self-perception score Interaction score Reading function score General function score Values for each subscale range from 0 to 100. 0 indicates poor quality of life (the patient reported "always" for all questions) and 100 represents good quality or life (patient reported "never" for all questions) |
12 months after enrollment
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Earl R Crouch, III, MD, Virginia Pediatric Eye Center
Publications and helpful links
General Publications
- Crouch ER, Dean TW, Kraker RT, Miller AM, Kraus CL, Gunton KB, Repka MX, Marsh JD, Del Monte MA, Luke PA, Peragallo JH, Lee KA, Wheeler MB, Daley TJ, Wallace DK, Cotter SA, Holmes JM; Pediatric Eye Disease Investigator Group. A prospective study of treatments for adult-onset divergence insufficiency-type esotropia. J AAPOS. 2021 Aug;25(4):203.e1-203.e11. doi: 10.1016/j.jaapos.2021.02.014. Epub 2021 Jul 13.
- Lorenzana IJ, Leske DA, Hatt SR, Dean TW, Jenewein EC, Dagi LR, Beal CJ, Pang Y, Retnasothie DV, Esposito CA, Erzurum SA, Aldrich AE, Crouch ER, Li Z, Kraker RT, Holmes JM, Cotter SA; Pediatric Eye Disease Investigator Group; Pediatric Eye Disease Investigator Group. Relationships among Clinical Factors and Patient-reported Outcome Measures in Adults with Convergence Insufficiency. Optom Vis Sci. 2022 Sep 1;99(9):692-701. doi: 10.1097/OPX.0000000000001929. Epub 2022 Aug 2.
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Central Nervous System Diseases
- Nervous System Diseases
- Eye Diseases
- Cranial Nerve Diseases
- Strabismus
- Ocular Motility Disorders
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Cholinergic Agents
- Membrane Transport Modulators
- Acetylcholine Release Inhibitors
- Botulinum Toxins
Other Study ID Numbers
- SAS1
- 2U10EY011751 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Convergence Insufficiency
-
Chen ZhaoShanghai Jiao Tong University School of Medicine; Children's Hospital of Fudan... and other collaboratorsCompletedConvergence Insufficiency Intermittent Exotropia (CI-IXT)China
-
Shahid Beheshti University of Medical SciencesUnknownComparison of Three Vision Therapy Approaches for Convergence InsufficiencyIran, Islamic Republic of
-
Salus UniversityUniversity of Alabama at Birmingham; National Eye Institute (NEI); Ohio State... and other collaboratorsUnknownConvergence InsufficiencyUnited States
-
Pennsylvania College of OptometryNational Eye Institute (NEI)CompletedConvergence InsufficiencyUnited States
-
Midwestern UniversitySouthern California College of Optometry at Marshall B. Ketchum University; New Jersey Institute of Technology and other collaboratorsRecruitingConvergence InsufficiencyUnited States
-
National Taiwan University HospitalNot yet recruitingConvergence InsufficiencyTaiwan
-
Shahid Beheshti University of Medical SciencesRecruitingConvergence InsufficiencyIran, Islamic Republic of
-
Salus UniversityUnknownConvergence InsufficiencyUnited States
-
New Jersey Institute of TechnologyNational Eye Institute (NEI)CompletedConvergence InsufficiencyUnited States
-
Ohio State UniversityCompletedConvergence InsufficiencyUnited States
Clinical Trials on Prism
-
VA Office of Research and DevelopmentRecruitingSpatial Neglect After Right Brain StrokeUnited States
-
Intuor Technologies, Inc.Completed
-
Intuor Technologies, Inc.Completed
-
Hospices Civils de LyonCompletedPrimary Health Care | Patient Safety | Risk ManagementFrance
-
Nova Scotia Health AuthorityNot yet recruitingSpatial Neglect
-
GrayMatters Health Ltd.CompletedPost-Traumatic Stress Disorder (PTSD)United States, Israel
-
University of Geneva, SwitzerlandNot yet recruitingUnilateral Spatial Neglect
-
University of MiamiCompletedSocial Isolation | Social Support (Formal and Informal) | Well-being/Quality of LifeUnited States
-
Kessler FoundationCompleted
-
Fondation Ophtalmologique Adolphe de RothschildTerminatedCentral Nervous System Diseases | Nervous System Diseases | Neurologic Manifestations | Movement Disorders | Dyskinesias | Dystonia | Dystonic Disorders | TorticollisFrance